Editas Medicine Achieves In Vivo Gene Editing Milestones, Plans Clinical Push
• Editas Medicine achieved in vivo preclinical proof of concept by editing hematopoietic stem cells in non-human primates, a crucial step for sickle cell disease and beta thalassemia treatment.
• The company demonstrated in vivo editing of liver cells in non-human primates and delivered to two additional cell types in humanized mice, expanding therapeutic possibilities.
• Editas anticipates declaring two in vivo development candidates by mid-2025, one for HSCs and one for the liver, alongside presenting further in vivo data.
• Strategic priorities through 2027 include submitting at least one IND/CTA and achieving human in vivo proof of concept in HSC editing for sickle cell disease and beta thalassemia.
© Copyright 2025. All Rights Reserved by MedPath